Enterprise Value
972.1M
Cash
403.9M
Avg Qtr Burn
-49.58M
Short % of Float
25.39%
Insider Ownership
2.24%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZORYVE® (ARQ-151) topical roflumilast cream (PDE4 Inhibitor) Details Psoriasis, Skin disease/disorder, Chronic obstructive pulmonary disease, Pulmonary hypertension | Approved Quarterly sales | |
ZORYVE® (ARQ-151) topical roflumilast cream (PDE4 Inhibitor) Details Skin disease/disorder, Psoriasis | Approved Quarterly sales | |
ARQ-151 topical roflumilast cream (PDE4 Inihibitor) Details Atopic dermatitis | Approved Quarterly sales | |
ZORYVE® (Roflumilast foam 0.3%) Details Skin disease/disorder, Seborrheic dermatitis | Approved Quarterly sales | |
ARQ-154 topical roflumilast foam (PDE4 inhibitor) Details Psoriasis, Skin disease/disorder | sNDA Acceptance for review | |
ARQ-151 topical roflumilast cream (PDE4 Inihibitor) Details Atopic dermatitis | sNDA Submission | |
ARQ-255 topical ivarmacitinib (JAK1 inhibitor) Details Skin disease/disorder, Alopecia areata | Phase 1b Data readout | |
ARQ-252 (JAK1i) Details Skin disease/disorder, Eczema | Failed Discontinued | |
ARQ-252 (JAKi) Details Vitiligo | Failed Discontinued |